197 related articles for article (PubMed ID: 31772615)
1. Comparison of the Effect of Fimasartan versus Valsartan on Blood Pressure Variability in Acute Ischemic Stroke: A Double-Blind Randomized Trial.
Shin DH; Song S; Lee YB
Cardiovasc Ther; 2019; 2019():7836527. PubMed ID: 31772615
[TBL] [Abstract][Full Text] [Related]
2. Ambulatory blood pressure response to once-daily fimasartan: an 8-week, multicenter, randomized, double-blind, active-comparator, parallel-group study in Korean patients with mild to moderate essential hypertension.
Lee H; Kim KS; Chae SC; Jeong MH; Kim DS; Oh BH
Clin Ther; 2013 Sep; 35(9):1337-49. PubMed ID: 23932463
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of 30-mg fimasartan for the treatment of patients with mild to moderate hypertension: an 8-week, multicenter, randomized, double-blind, phase III clinical study.
Youn JC; Ihm SH; Bae JH; Park SM; Jeon DW; Jung BC; Park TH; Lee NH; Song JM; Yoon YW; Shin ES; Sung KC; Jung IH; Pyun WB; Joo SJ; Park WJ; Shin JH; Kang SM
Clin Ther; 2014 Oct; 36(10):1412-21. PubMed ID: 25092393
[TBL] [Abstract][Full Text] [Related]
4. Fimasartan versus perindopril with and without diuretics in the treatment of elderly patients with essential hypertension (Fimasartan in the Senior Subjects (FITNESS)): study protocol for a randomized controlled trial.
Kang MG; Kim KI; Ihm SH; Rhee MY; Sohn IS; Lee HY; Park S; Jeon ES; Song JM; Pyun WB; Sung KC; Kim MH; Kim SH; Kim SY; Kim SJ; Kim EJ; Shin J; Lee SY; Chun KJ; Jeong JO; Chae SC; Yoo KD; Choi YJ; Park YH; Kim CH
Trials; 2019 Jul; 20(1):389. PubMed ID: 31262348
[TBL] [Abstract][Full Text] [Related]
5. Effect of Fimasartan versus Valsartan and Olmesartan on Office and Ambulatory Blood Pressure in Korean Patients with Mild-to-Moderate Essential Hypertension: A Randomized, Double-Blind, Active Control, Three-Parallel Group, Forced Titration, Multicenter, Phase IV Study (Fimasartan Achieving Systolic Blood Pressure Target (FAST) Study).
Chung WB; Ihm SH; Jang SW; Her SH; Park CS; Lee JM; Chang K; Jeon DS; Yoo KD; Seung KB
Drug Des Devel Ther; 2020; 14():347-360. PubMed ID: 32158190
[TBL] [Abstract][Full Text] [Related]
6. A Randomized, Double-blind, Candesartan-controlled, Parallel Group Comparison Clinical Trial to Evaluate the Antihypertensive Efficacy and Safety of Fimasartan in Patients with Mild to Moderate Essential Hypertension.
Lee JH; Yang DH; Hwang JY; Hur SH; Cha TJ; Kim KS; Kim MH; Chun KJ; Cha GS; Hong GR; Lee SG; Kim DS; Kim DI; Chae SC
Clin Ther; 2016 Jun; 38(6):1485-1497. PubMed ID: 27161546
[TBL] [Abstract][Full Text] [Related]
7. 24-Hour blood pressure response to lower dose (30 mg) fimasartan in Korean patients with mild to moderate essential hypertension.
Lee HY; Kim CH; Song JK; Chae SC; Jeong MH; Kim DS; Oh BH
Korean J Intern Med; 2017 Nov; 32(6):1025-1036. PubMed ID: 29032666
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and tolerability of once-daily oral fimasartan 20 to 240 mg/d in Korean Patients with hypertension: findings from Two Phase II, randomized, double-blind, placebo-controlled studies.
Lee H; Yang HM; Lee HY; Kim JJ; Choi DJ; Seung KB; Jeon ES; Ha JW; Rim SJ; Park JB; Shin JH; Oh BH
Clin Ther; 2012 Jun; 34(6):1273-89. PubMed ID: 22608107
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and tolerability of fimasartan, a new angiotensin receptor blocker, compared with losartan (50/100 mg): a 12-week, phase III, multicenter, prospective, randomized, double-blind, parallel-group, dose escalation clinical trial with an optional 12-week extension phase in adult Korean patients with mild-to-moderate hypertension.
Lee SE; Kim YJ; Lee HY; Yang HM; Park CG; Kim JJ; Kim SK; Rhee MY; Oh BH;
Clin Ther; 2012 Mar; 34(3):552-568, 568.e1-9. PubMed ID: 22381711
[TBL] [Abstract][Full Text] [Related]
10. Central and cerebral haemodynamic changes after antihypertensive therapy in ischaemic stroke patients: A double-blind randomised trial.
Choi MH; Lee JS; Lee SE; Lee SJ; Yoon D; Park RW; Hong JM
Sci Rep; 2018 Jan; 8(1):1556. PubMed ID: 29367614
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of fimasartan/hydrochlorothiazide combination in hypertensive patients inadequately controlled by fimasartan monotherapy.
Rhee MY; Baek SH; Kim W; Park CG; Park SW; Oh BH; Kim SH; Kim JJ; Shin JH; Yoo BS; Rim SJ; Ha JW; Doh JH; Ahn Y; Chae JK; Park JB; Kim SK; Kim CH
Drug Des Devel Ther; 2015; 9():2847-54. PubMed ID: 26082615
[TBL] [Abstract][Full Text] [Related]
12. Clinic and Home Blood Pressure Lowering Effect of an Angiotensin Receptor Blocker, Fimasartan, in Postmenopausal Women with Hypertension.
Kim SY; Joo SJ; Shin MS; Kim C; Cho EJ; Sung KC; Kang SM; Kim DS; Lee SH; Hwang KK; Park JB
Medicine (Baltimore); 2016 May; 95(22):e3764. PubMed ID: 27258507
[TBL] [Abstract][Full Text] [Related]
13. A home blood pressure monitoring study comparing the antihypertensive efficacy of two angiotensin II receptor antagonist fixed combinations.
Bobrie G; Delonca J; Moulin C; Giacomino A; Postel-Vinay N; Asmar R;
Am J Hypertens; 2005 Nov; 18(11):1482-8. PubMed ID: 16280286
[TBL] [Abstract][Full Text] [Related]
14. The efficacy and safety of co-administration of fimasartan and rosuvastatin to patients with hypertension and dyslipidemia.
Rhee MY; Ahn T; Chang K; Chae SC; Yang TH; Shim WJ; Kang TS; Ryu JK; Nah DY; Park TH; Chae IH; Park SW; Lee HY; Tahk SJ; Yoon YW; Shim CY; Shin DG; Seo HS; Lee SY; Kim DI; Kwan J; Joo SJ; Jeong MH; Jeong JO; Sung KC; Kim SY; Kim SH; Chun KJ; Oh DJ
BMC Pharmacol Toxicol; 2017 Jan; 18(1):2. PubMed ID: 28057081
[TBL] [Abstract][Full Text] [Related]
15. FimAsartaN proTeinuriA SusTaIned reduCtion in comparison with losartan in diabetic chronic kidney disease (FANTASTIC): study protocol for randomized controlled trial.
Kim JY; Son JW; Park S; Yoo TH; Kim YJ; Ryu DR; Chin HJ
Trials; 2017 Dec; 18(1):632. PubMed ID: 29284530
[TBL] [Abstract][Full Text] [Related]
16. Fimasartan, a novel angiotensin II receptor antagonist.
Kim JH; Lee JH; Paik SH; Kim JH; Chi YH
Arch Pharm Res; 2012 Jul; 35(7):1123-6. PubMed ID: 22864732
[TBL] [Abstract][Full Text] [Related]
17. Effects of doxazosin mesylate versus nifedipine on blood pressure variability in hypertensive patients: a randomized crossover study (SIMILAR).
Shi J; Liang D; Pan Y; Zhang S; He M; Zhang H; Liu G; Gong Y; Wang W; Cang H; Li Y
Blood Press Monit; 2019 Oct; 24(5):252-258. PubMed ID: 31116151
[TBL] [Abstract][Full Text] [Related]
18. A randomized placebo controlled trial of early treatment of acute ischemic stroke with atorvastatin and irbesartan.
Beer C; Blacker D; Bynevelt M; Hankey GJ; Puddey IB
Int J Stroke; 2012 Feb; 7(2):104-11. PubMed ID: 22044557
[TBL] [Abstract][Full Text] [Related]
19. Safety, tolerability, pharmacokinetics, and pharmacodynamics of fimasartan following single and repeated oral administration in the fasted and fed states in healthy subjects.
Chi YH; Lee H; Paik SH; Lee JH; Yoo BW; Kim JH; Tan HK; Kim SL
Am J Cardiovasc Drugs; 2011 Oct; 11(5):335-46. PubMed ID: 21910510
[TBL] [Abstract][Full Text] [Related]
20. Effects of the angiotensin II receptor blockers telmisartan versus valsartan on the circadian variation of blood pressure: impact on the early morning period.
White WB; Lacourciere Y; Davidai G
Am J Hypertens; 2004 Apr; 17(4):347-53. PubMed ID: 15062889
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]